These results suggested that MET, a potential pharmacological inhibitor of VEGF-B signaling pathway, potentiated the anti-tumor effect of RSV on PaCa, and combination of MET and RSV would be a promising modality for clinical PaCa therapy. This evidence concerns the gene MET and permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.